Pearl Abyss (263750.KQ) just crossed 5 million copies of Crimson Desert. We break down why 7.5M is now a floor, what the free update roadmap really means for long-tail monetization, and where the real re-rating triggers lie.
NextBiomedical investment analysis. Nexpowder hemostatic agent in commercialization phase across 30+ countries via Medtronic. Nexphere-F absorbable embolization microsphere in US pivotal trial with FDA Breakthrough Device Designation. 2025 revenue KRW 16.5B, OP loss KRW 735M. HS code export data-based Q1 2026 estimates and analyst target price reverse-engineering.
Deep-dive on Pharma Research Products (214450.KQ), the Korean KOSDAQ company behind Rejuran PDRN skin boosters riding the global K-beauty aesthetics wave.
Deep-dive into Samsung Electronics (005930.KS): HBM memory, Galaxy, and foundry ambitions—what global investors need to know about Korea's tech crown jewel.